Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 4/20 | 0.33 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29566654 | 0.89 | NMT1 (0.37) | CACNA1BSRCTSHRSMN1; SMN2CACNA1H | |
| SCHEMBL24310059 | 0.89 | NMT1 (0.37) | CACNA1BSRCTSHRSMN1; SMN2CACNA1H | |
| SCHEMBL26810238 | 0.88 | SMN1; SMN2 (0.38) | CDK2TSHRSMN1; SMN2PIK3CDPIK3CB | |
| SCHEMBL26856825 | 0.88 | MKNK1 (0.38) | CACNA1BCDK2SRCTSHRSMN1; SMN2 | |
| SCHEMBL26856978 | 0.86 | CACNA1B (0.37) | CACNA1BSRCCACNA1HPIK3CDPIK3CB | |
| SCHEMBL29566612 | 0.86 | TSHR (0.43) | TSHRSMN1; SMN2PIK3CDPIK3CBMTOR | |
| SCHEMBL24310345 | 0.86 | TSHR (0.43) | TSHRSMN1; SMN2PIK3CDPIK3CBMTOR | |
| SCHEMBL29566748 | 0.85 | GAA (0.40) | TSHRSMN1; SMN2PIK3CDPIK3CBMTOR | |
| SCHEMBL24310086 | 0.85 | GAA (0.40) | TSHRSMN1; SMN2PIK3CDPIK3CBMTOR | |
| SCHEMBL26810218 | 0.85 | KMT2A (0.40) | TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CACNA1B 1648/4885CDK2 4552/4885SRC 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.